Y-mAbs down as FDA declines to approve co's pediatric cancer drug

Y-mAbs Therapeutics

01/12/2022 22:51

** Shares of Y-mAbs Therapeutics Inc  YMAB.O  down 15.7% at
$3.79 in extended trading 
    ** FDA declines to approve treatment from YMAB for a rare
form of nerve cancer in pediatric patients  urn:newsml:reuters.com:*:nL4N32R442
    ** FDA's decision follows a unanimous vote by its advisers
in October against the drug
    ** As of last close, stock fell ~72% this year
 (Reporting by Tiyashi Datta in Bengaluru)
 ((tiyashi.datta@thomsonreuters.com))